+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of baricitinib in treating severe or very severe alopecia areata, a type of hair loss, in children aged 6 to less than 18 years. This Phase 3 trial includes children and adolescents with severe alopecia areata lasting at least one year and aims to understand how baricitinib helps improve their condition compared to placebo. Participants will be randomly assigned to one of three groups baricitinib high dose, baricitinib low dose, or placebo, all taken orally. The study includes a 5-week screening period, a 36-week double-blind treatment period, an approximately 2-year long-term extension period, and a 4-week post-treatment follow-up. Some participants may qualify for additional treatment after the extension period lasting up to 180 weeks. During the study, participants will have regular assessments including hair loss severity scores, patient and clinician reported outcomes, anxiety and depression scales, and pharmacokinetic tests. Safety and effects on quality of life will be monitored throughout, with follow-ups after treatment ends. Total participation may last several years depending on the study phase and extension.

Age: 6Years - 17YearsAll GendersPhase 3
127 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, effectiveness, tolerability, and how the body processes OLX72021 in medically healthy men aged 18 to 59 years with mild to moderate androgenetic alopecia. This study is a Phase 1b2a randomized, placebo-controlled trial using multiple ascending doses of OLX72021 to better understand its effects on hair growth and safety in this population. Participants will be divided into groups receiving different doses of OLX72021 or placebo. In Phase 1b, two dose levels are given sequentially, each with 12 participants receiving three intradermal injections spaced 28 days apart. Phase 2a involves four groups, including one placebo group and three OLX72021 groups, with six intradermal treatments given 28 days apart. The study uses a double-blind design to compare the drug to placebo. Throughout the study, participants will have regular visits for treatment and monitoring, including assessments of adverse events, injection site reactions, and changes in hair count up to 24 weeks. Additional evaluations include pharmacokinetics, patient questionnaires about hair growth, and investigator assessments. Blood draws and safety monitoring will be performed, with the total study duration lasting up to approximately 24 weeks for primary outcome measurement.

Age: 18Years - 59YearsMALEPhase 1Phase 2
8 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of different doses of IMG-007 compared to placebo in adults with moderate-to-severe active atopic dermatitis. This Phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to understand how well IMG-007 works and its safety profile over a period of up to 48 weeks. Participants will receive subcutaneous injections of IMG-007 or placebo according to the study protocol. The study includes multiple dose regimens of IMG-007 and placebo groups, with some placebo participants crossing over to receive IMG-007 later. Treatments follow a parallel group design where different groups receive different doses or placebo. During the study, participants will undergo assessments including Eczema Area and Severity Index EASI scoring and Investigator Global Assessment for Atopic Dermatitis vIGA-AD at baseline and Week 24. Researchers will monitor treatment-emergent adverse events throughout the study. Participants will be followed for up to 48 weeks to evaluate changes in skin condition and safety outcomes during and after treatment.

Age: 18Years - 74YearsAll GendersPhase 2
30 locations
C

Actively Recruiting

This research aims to provide continued access to the drug anifrolumab for participants who have completed a previous clinical study and are assessed by the Investigator to still benefit from ongoing treatment. The study focuses on monitoring the long-term safety and tolerability of anifrolumab in people with conditions including Systemic Sclerosis, Cutaneous Lupus, Myopathies, and Systemic Lupus Erythematosus. Participants must have received at least one dose of anifrolumab in the prior study and be considered suitable to continue treatment. Participants will receive anifrolumab in the same form and manner as in the parent trial, which may be via pre-filled syringe, pre-filled pen, or infusion. This is an open-label study without randomization, where all participants continue on anifrolumab until they meet study discontinuation criteria. Those with treatment gaps or on compassionate use can also enroll. The study enrollment visit occurs at the end of the parent study after all safety follow-up assessments are complete. Throughout the study, safety monitoring includes collecting data on serious and non-serious adverse events from the first dose until 12 weeks after the last dose of anifrolumab. Participants will be followed until they discontinue, with ongoing assessments of tolerability. The study duration extends until December 2032, allowing long-term observation of treatment effects and safety.

Age: 5Years - 80YearsAll GendersPhase 3
153 locations